最高“猛砍”90%！

Core Viewpoint - The valuation of Nohui Health has been drastically reduced by multiple fund companies, reflecting a pessimistic outlook on its prospects for resuming trading after a prolonged suspension [2][4][9]. Valuation Adjustments - On June 25, Changcheng Fund announced a new valuation of Nohui Health at 1.20 HKD per share, a 91.51% decrease from its last trading price of 14.14 HKD [7][12]. - Since mid-last year, over 40 valuation adjustments have been made by various fund companies, with Dachen Fund reducing its valuation from 10.12 HKD to 1.81 HKD [9][11]. - Shanghai Guangzheng Asset Management has also adjusted its valuation four times, from 12.73 HKD to 5.70 HKD [9]. Company Background - Nohui Health, once known as "China's first cancer screening stock," was listed on the Hong Kong Stock Exchange in February 2021 and focuses on the development and commercialization of screening products for colorectal, gastric, and cervical cancers [11]. - The company faced allegations of financial misconduct, with a report claiming its actual sales in 2022 were only 76.95 million, significantly lower than the reported 765 million [11]. Suspension and Future Risks - Nohui Health has been suspended from trading since March 28, 2024, due to its inability to publish its annual report on time [12]. - According to Hong Kong Stock Exchange regulations, if the suspension lasts for 18 months, the company may face mandatory delisting, leaving it with approximately three months before this deadline [13].